CSL Ltd (ASX: CSL) shares had a brutal FY 2026.
Over the 12 months to 30 June, the healthcare giant's share price crashed by around 50%.
That is a staggering fall for a company of its stature.
So, what went wrong?
Image source: Getty Images
CSL shares sold off
A big reason for the selloff was that investors lost confidence in CSL's earnings trajectory.
The company entered the year with the market still expecting a recovery in margins, stronger plasma earnings, vaccine progress, and better returns from its Vifor acquisition.
Instead, the year brought a series of disappointments.
In October, CSL downgraded its profit outlook after weaker US flu vaccination rates hurt its Seqirus vaccines business. It also delayed the planned spin-off of Seqirus, which had been expected to help simplify the group and unlock value.
That was followed by a difficult half-year result in February, when CSL reported a major slump in statutory profit and announced the sudden exit of CEO Paul McKenzie.
The pressure then intensified in May, when interim CEO Gordon Naylor completed a 90-day review and cut FY 2026 guidance again.
CSL lowered its revenue expectations to around US$15.2 billion and net profit after tax to approximately US$3.1 billion. It also flagged about US$5 billion of additional pre-tax non-cash impairment charges across FY 2026 and FY 2027.
That left investors questioning whether CSL's recovery was simply taking longer than expected, or whether the market had overestimated the strength of the company's growth profile.
Underperformance across key businesses
The downgrade was not tied to one small issue.
CSL faced pressure across its operations, including weaker flu vaccine demand, slower benefits from its growth initiatives, underperformance in parts of the Vifor portfolio, and challenges in markets such as China albumin and US immunoglobulin.
And while the company still has major strengths in plasma collections, influenza vaccines, iron deficiency products, and specialist medicines, FY 2026 showed that even high-quality healthcare businesses can disappoint when expectations, execution, and market conditions move against them at the same time.
Leadership and tariff concerns added pressure
As mentioned above, the CEO change also unsettled investors.
A sudden leadership exit during a period of earnings pressure can make the market nervous, particularly when a company is already trying to restore confidence.
Tariff concerns added another layer of uncertainty. Healthcare companies with global supply chains and US exposure were closely watched as investors assessed the potential impact of trade policy changes. CSL later indicated that life-saving medicines may be protected from major direct impacts, but the uncertainty still weighed on sentiment and its shares during the year.
A painful reset
CSL's FY 2026 share price crash was caused by more than ordinary market volatility.
It reflected a painful reset in expectations after guidance downgrades, business underperformance, impairments, leadership uncertainty, and broader policy concerns.
The company still owns valuable global healthcare assets, but FY 2026 reminded investors that even blue-chip growth shares can fall heavily when the earnings story breaks down.
Here's hoping FY 2027 will be a much better year for CSL shares.
